Sanofi Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab an Investigational Treatment for Rheumatoid Arthritis

Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab an Investigational Treatment for Rheumatoid Arthritis Paris and Tarrytown N.Y. October 28 2016 Sanofi and Regeneron Phar…
Read the full story: Bioportfolio Latest News